MBRX: Moleculin Biotech, Inc. Stock

by  •  • Comments Off on MBRX: Moleculin Biotech, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 12.87
Enterprise Value ($M) 8.59
Book Value ($M) 5.98
Book Value / Share 0.43
Price / Book 2.15
NCAV ($M) -5.75
NCAV / Share -0.41
Price / NCAV -2.24

Profitability (mra)
Return on Invested Capital (ROIC) -3.37
Return on Assets (ROA) -0.71
Return on Equity (ROE) -1.01

Liquidity (mrq)
Quick Ratio 0.97
Current Ratio 0.97

Balance Sheet (mrq) ($M)
Current Assets 5.19
Assets 16.93
Liabilities 10.95
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -26.64
Net Income -21.76
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -23.86
Cash from Investing -0.01
Cash from Financing 4.63

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Armistice Capital, Llc 9.99 12.88

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-18 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPO
2025-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 60,500 259,845 23.28
2025-04-16 302,062 852,309 35.44
2025-04-15 55,171 184,410 29.92
2025-04-14 79,874 239,738 33.32

(click for more detail)

Similar Companies
LSTA – Lisata Therapeutics, Inc. LTRN – Lantern Pharma Inc.
MBIO – Mustang Bio, Inc. MEIP – MEI Pharma, Inc.
MIRA – MIRA Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Moleculin Biotech